Your Healthcare Team Q&A for Your Team

Questions to ask your healthcare team

You have the most important role on your healthcare team. There are many things that only you know about yourself, your health, your lifestyle, your family, your values and your preferences. All of that knowledge is important for developing a treatment plan that works for you. You and your healthcare team should take all that information into consideration when you are preparing a treatment plan.

Some things you should discuss with your healthcare team:

  • What you eat and drink regularly, including alcohol
  • Recent changes in your body weight
  • Whether you exercise, what type of exercise, and how often
  • Any health complaints or symptoms you have experienced recently
  • What kind of support you have from family and friends the costs of any treatments, including other specialists, and what is covered by insurance
  • Your mood and motivation to follow through on any treatment plans
  • Your values, preferences, family factors, and cultural factors that affect your ability or desire to follow a treatment plan

Your treatment plan

You and your healthcare team should develop a treatment plan to reduce your triglyceride levels. That plan should be compatible with other health problems and concerns you may have.

Some things you should discuss with your healthcare team:

  • What is the goal of my treatment? What is my target triglyceride level?
  • How soon should I see changes in my triglyceride levels?
  • What should I do if I have trouble following nutrition advice, exercising, reducing alcohol consumption, taking medication or following through on other parts of my treatment plan?
  • How will my treatment affect my diabetes, obesity, heart disease, or any other health problems or concerns?
  • How can I get and stay motivated?
  • How does my treatment plan work with other aspects of my life: work, family life, social life, etcetera?
  • How long do I need to keep following the treatment plan?

If your treatment plan includes use of medications, here are some questions to ask your doctor about those medications:

  • Does my medication include a patient guide or information sheet?
  • What side effects could this medication have? What should I do if I have side effects?
  • Is it safe to take this medication with the other medications, supplements, and remedies I’m taking?
  • Are there any special instructions I must follow while I’m taking this medication (such as not drinking or eating grapefruit products, or staying out of the sun, for example)
  • How much should this medication reduce my triglyceride levels?
  • What happens if I miss a dose, or take an extra dose?
  • Do I need to take at a certain time of day? With or without meals?
  • How often do I take the medications? Is there a once-daily form?
  • How long will I need to take this medication?
  • How much will it cost me?
  • What other medications are there? What are the advantages and disadvantages of each?

Seeing a Specialist

If you see a specialist, your primary care doctor is still an important part of your healthcare team and should know about all your treatments and treatment plans.

Also, you are still the most important member of your healthcare team. If you play an active part on that team, your specialist will have a better chance to help you.

If you are referred to a specialist, it is helpful to bring with you the following information.33

  • Results of all your laboratory tests, including any genetic tests you may have had
  • The diagnosis related to severe hypertriglyceridemia (sHTG) given to you by your primary care doctor
  • A list of all the medications you are taking, including doses and how often you take them, over-the-counter medications, dietary supplements, herbal supplements, and any other remedies
  • Information about any other medical conditions you have or have had in the past
  • Information about your family history
  • Your current treatment plan Information about how well you have been sticking to your treatment plan
  • Information about other medications you have used in the past to lower triglyceride levels and how well they worked.
Show References
 
  • 1. Laufs U, Parhofer KG, Ginsberg HN, Hegele RA. Clinical review on triglycerides. Eur Heart J. 2020;41(1):99-109c.
  • 2. Ginsberg HN, Packard CJ, Chapman MJ, Borén J, Aguilar-Salinas CA, Averna M, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42(47):4791-806.
  • 3. Virani SS, Morris PB, Agarwala A, Ballantyne CM, Birtcher KK, Kris-Etherton PM, et al. 2021 ACC Expert Consensus Decision Pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: A report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021.
  • 4. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384(9943):626-35.
  • 5. Packard CJ. Remnants, LDL, and the quantification of lipoprotein-associated risk in atherosclerotic cardiovascular disease. Curr Atheroscler Rep. 2022;24(1534-6242 (Electronic)):133-42.
  • 6. Wang Y. Higher fasting triglyceride predicts higher risks of diabetes mortality in US adults. Lipids Health Dis. 2021;20(1):181.
  • 7. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285-e350.
  • 8. Chyzhyk V, Brown AS. Familial chylomicronemia syndrome: A rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis. Trends Cardiovasc Med. 2020;30(2):80-5.
  • 9. National Lipid Association. Lifestyle changes to reduce triglycerides: Advice from the National Lipid Association Clinician’s Lifestyle Modification Toolbox. https://www.lipid.org/sites/default/files/lifestyle_changes_to_reduce_triglycerides.final_edits.7.17.16_0.pdf.
  • 10. Santos-Baez LS, Ginsberg HN. Hypertriglyceridemia-causes, significance, and approaches to therapy. Front Endocrinol (Lausanne). 2020;11:616.
  • 11. Sandesara PB, Virani SS, Fazio S, Shapiro MD. The forgotten lipids: Triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk. Endocr Rev. 2019;40(2):537-57.
  • 12. Carrasquilla GD, Christiansen MR, Kilpeläinen TO. The genetic basis of hypertriglyceridemia. Curr Atheroscler Rep. 2021;23(8):39.
  • 13. Dron JS, Dilliott AA, Lawson A, McIntyre AD, Davis BD, Wang J, et al. Loss-of-function CREB3L3 variants in patients with severe hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 2020;40(8):1935-41.
  • 14. Javvaji A, Can AS, Sharma S. Dysbetalipoproteinemia. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2023, StatPearls Publishing LLC.; 2023.
  • 15. Moulin P, Dufour R, Averna M, Arca M, Cefalù AB, Noto D, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score". Atheroscler. 2018;275:265-72.
  • 16. Nawaz H, Koutroumpakis E, Easler J, Slivka A, Whitcomb DC, Singh VP, et al. Elevated serum triglycerides are independently associated with persistent organ failure in acute pancreatitis. Am J Gastroenterol. 2015;110(10):1497-503.
  • 17. Stroes E, Moulin P, Parhofer KG, Rebours V, Löhr JM, Averna M. Diagnostic algorithm for familial chylomicronemia syndrome. Atheroscler Suppl. 2017;23:1-7.
  • 18. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.
  • 19. Koehler EM, Schouten JN, Hansen BE, Hofman A, Stricker BH, Janssen HL. External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. Clin Gastroenterol Hepatol. 2013;11(9):1201-4.
  • 20. Nivukoski U, Niemelä M, Bloigu A, Bloigu R, Aalto M, Laatikainen T, et al. Combined effects of lifestyle risk factors on fatty liver index. BMC Gastroenterol. 2020;20(1):109.
  • 21. Paquette M, Bernard S. The evolving story of multifactorial chylomicronemia syndrome. Front Cardiovasc Med. 2022;9:886266.
  • 22. Vincent AM, Hinder LM, Pop-Busui R, Feldman EL. Hyperlipidemia: a new therapeutic target for diabetic neuropathy. J Peripher Nerv Syst. 2009;14(4):257-67.
  • 23. Benefits of physical activity: Center for Disease Control and Prevention. [https://www.cdc.gov/physicalactivity/basics/pa-health/index.htm.
  • 24. Tari AR, Nauman J, Zisko N, Skjellegrind HK, Bosnes I, Bergh S, et al. Temporal changes in cardiorespiratory fitness and risk of dementia incidence and mortality: a population-based prospective cohort study. Lancet Public Health. 2019;4(11):e565-e74.
  • 25. Whole person health: What you need to know: National Center for Complementary and Integrative Health. [https://www.nccih.nih.gov/health/whole-person-health-what-you-need-to-know.
  • 26. Berglund L, Brunzell J, Sacks FM. Patient information page from The Hormone Foundations. Patient guide to the assessment and treatment of hypertriglyceridemia (high triglycerides). J Clin Endocrinol Metab. 2012;97(9):31a-2a.
  • 27. Ito MK. Chapter 6. Patient-centered care. In: Gogia S, editor. Fundamentals of Telemedicine and Telehealth: Academic Press; 2020:115-126.
  • 28. Barry MJ, Edgman-Levitan S. Shared decision making--pinnacle of patient-centered care. N Engl J Med. 2012;366(9):780-1.
  • 29. Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley P, et al. Shared decision making: a model for clinical practice. J Gen Intern Med. 2012;27(10):1361-7.
  • 30. Jacobson TA, Maki KC, Orringer CE, Jones PH, Kris-Etherton P, Sikand G, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 2. J Clin Lipidol. 2015;9(6 Suppl):S1-122.e1.
  • 31. Banerji A, Anderson J, Johnston DT. Optimal management of hereditary angioedema: Shared decision-making. J Asthma Allergy. 2021;14:119-25.
  • 32. Zeman H, Cavanaugh E, Metallinos-Katsaras E, Ireland K, Pojednic R. Improved long-term outcomes in high-risk patients receiving registered dietitian nutritionist care. Endocr Metab Sci. 2021;2:100078.
  • 33. Morrell J, Wierzbicki T. 10 Steps before you refer for: Lipids. Br J Cardiol. 2009;16:242-5.
  • 34. Davidson M, Stevenson M, Hsieh A, Ahmad Z, Roeters van Lennep J, Crowson C, et al. The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study. J Clin Lipidol. 2018;12(4):898-907.e2.
  • 35. Lipid Panel: Cleveland Clinic. [https://my.clevelandclinic.org/health/diagnostics/17176-lipid-panel.
  • 36. Academy of Nutrition and Dietetics. Medical nutrition therapy (MNT) systematic review [https://www.andeal.org/topic.cfm?menu=3949.

Your are about to leave KnowYourTGs.com

You will be taken to a website independently operated and not managed by Ionis Pharmaceuticals. Ionis Pharmaceuticals assumes no responsibility for the content of the site.

Thank you for visiting KnowYourTGs.com